| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 29, 2014Medtronic Commits to Further Clinical Investigation and Determining Path Forward for Next U.S. IDE with FDA
MINNEAPOLIS and WASHINGTON, DC - March 29, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the full results of the SYMPLICITY HTN-3 clinical trial, which were presented today in late-breaking...
-
Feb 18, 2014Revenue of $4.2 Billion Grew 4% on a Constant Currency Basis; 3% as Reported
MINNEAPOLIS - Feb. 18, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2014, which ended January 24, 2014. The company reported worldwide...
-
Jan 24, 2014Net sales up 3% (up 5%, excluding foreign exchange rate movement); Medical Devices sales up 3% (up 6%, excluding foreign exchange rate movement)
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 24, 2014-- Covidien plc (NYSE: COV) today announced financial results for the first quarter of fiscal 2014 (October - December 2013). First-quarter net sales of
-
Jan 21, 2014
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 21, 2014-- Covidien plc (NYSE: COV) today announced it will exit its OneShot™ Renal Denervation program. This voluntary action is primarily in response to...
-
Jan 9, 2014
MINNEAPOLIS - January 9, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that its U.S. pivotal trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, failed to meet...